Latest Period
Q2 2026
Security Snapshot
Compass Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CMPX) Institutional Ownership
CUSIP: 20454B104
13F Institutional Holders and Ownership History from Q4 2021 to Q2 2026
Institutions Reporting
215
Shares (Excl. Options)
165,544,323
Price
$2.19
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- CMPX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 165,544,323
- Total 13F value
- $362,522,516
- Portfolio coverage rank
- 0%
- Share change
- -8,691,027
- Value change
- -$119,570,579
- Number of holders
- 215
- Shares outstanding
- 180,189,325
- SEC-reported price per share
- $2.26
- Insider filing price
- $2.26
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CMPX - Compass Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 20454B104.
- 215 institutions reported positions in Q2 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 199 to 215 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $916,047,041 to $362,522,516.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 215 institutions filings for Q2 2026.
Security key
20454B104
Latest holder period
Q2 2026
13F holders
215
13D/G owners
11
CIK / CUSIP context first
Open Q2 2026 holders
CMPX full holder history
Compass Therapeutics, Inc. SEC filings
Compass Therapeutics, Inc. company facts
Compass Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 20454B104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
CMPX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 10% | +1.9% | $60,117,785 | +$12,881,057 | 17,176,510 | +27% | TANG CAPITAL MANAGEMENT, LLC | 30 Sep 2025 |
| ORBIMED ADVISORS LLC | 8.9% | -19% | $41,093,984 | 15,219,994 | 0% | ORBIMED ADVISORS LLC | 13 Aug 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 8.2% | +60% | $44,559,662 | +$21,967,265 | 14,101,159 | +97% | Suvretta Capital Management, LLC | 13 Aug 2025 |
| STATE STREET CORP | 5.5% | $21,798,500 | 9,953,653 | STATE STREET CORPORATION | 30 Jun 2026 | |||
| BlackRock, Inc. | 5.2% | +12% | $49,788,728 | +$15,426,163 | 9,271,644 | +45% | BlackRock, Inc. | 31 Dec 2025 |
| Commander Aggregator, LP | 4.5% | $24,610,554 | 7,788,150 | Commander Aggregator, LP | 14 Aug 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 4.3% | -16% | $41,076,014 | -$5,211,486 | 7,764,842 | -11% | BVF PARTNERS L P/IL | 31 Mar 2026 |
| Vivo Opportunity Fund Holdings, L.P. | 4% | -22% | $15,784,585 | -$3,916,609 | 7,207,573 | -20% | Vivo Opportunity Fund Holdings, L.P. | 30 Jun 2026 |
| Blackstone Holdings II L.P. | 3.4% | $31,917,408 | 6,126,182 | Blackstone Alternative Asset Management Associates LLC | 31 Dec 2025 | |||
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.4% | $11,629,931 | 5,994,810 | Adage Capital Management, L.P. | 31 Dec 2024 | |||
| MPM BioImpact LLC | 4.1% | -35% | $15,180,764 | -$7,952,556 | 5,622,505 | -34% | MPM BioImpact LLC | 30 Jun 2025 |
As of 30 Jun 2026, 215 institutional investors reported holding 165,544,323 shares of Compass Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CMPX). This represents 92% of the company’s total 180,189,325 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
77%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 10% | 17,990,782 | +7.1% | 1.8% | $39,399,813 |
| ORBIMED ADVISORS LLC | 8.4% | 15,219,994 | 0% | 0.63% | $33,331,787 |
| MONTANOVA CAPITAL, LLC | 7.8% | 14,101,159 | -1.4% | 0.65% | $30,881,538 |
| BlackRock, Inc. | 6.3% | 11,281,781 | +19% | 0% | $24,707,100 |
| STATE STREET CORP | 5.5% | 9,953,653 | +49% | 0% | $21,798,500 |
| ENAVATE SCIENCES GP, LLC | 4.3% | 7,788,150 | 0% | 4.9% | $17,056,049 |
| Vivo Capital, LLC | 4.3% | 7,757,060 | -19% | 1.6% | $16,987,961 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.4% | 6,118,782 | +1.4% | 0% | $13,400,133 |
| Palo Alto Investors LP | 3.2% | 5,831,813 | +285% | 1.8% | $12,771,670 |
| MILLENNIUM MANAGEMENT LLC | 2.6% | 4,713,247 | +457% | 0.01% | $10,322,011 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.1% | 3,815,189 | +7% | 0% | $8,357,450 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.1% | 3,771,032 | +248% | 0% | $8,258,560 |
| Qube Research & Technologies Ltd | 2% | 3,687,489 | +45% | 0.01% | $8,075,601 |
| Blue Owl Capital Holdings LP | 2% | 3,624,076 | +23% | 1.2% | $7,936,726 |
| CITADEL ADVISORS LLC | 2% | 3,570,674 | +395% | 0% | $7,819,776 |
| GOLDMAN SACHS GROUP INC | 2% | 3,531,000 | +77% | 0% | $7,732,890 |
| Rock Springs Capital Management LP | 2% | 3,524,929 | +6.6% | 0.38% | $7,719,595 |
| AQR CAPITAL MANAGEMENT LLC | 1.9% | 3,509,137 | +1651% | 0% | $7,685,011 |
| Birchview Capital, LP | 0.93% | 1,675,000 | +14% | 1.7% | $3,668,250 |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 0.78% | 1,400,000 | 0.41% | $3,066,000 | |
| Fisher Asset Management, LLC | 0.77% | 1,391,890 | +3.2% | 0% | $3,048,238 |
| ROYCE & ASSOCIATES LP | 0.74% | 1,336,780 | -17% | 0.02% | $2,927,548 |
| FMR LLC | 0.67% | 1,212,196 | -33% | 0% | $2,654,709 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.66% | 1,186,500 | -86% | 0% | $2,598,435 |
| ACADIAN ASSET MANAGEMENT LLC | 0.64% | 1,161,231 | 0% | $2,537,000 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
19
Latest
Q2 2026
Rows shown
1-19 of 19
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 165,544,323 | $362,522,516 | -$119,570,579 | $2.19 | 215 |
| 2026 Q1 | 173,194,999 | $916,047,041 | +$49,017,701 | $5.29 | 199 |
| 2025 Q4 | 164,168,134 | $881,588,986 | +$65,007,494 | $5.37 | 174 |
| 2025 Q3 | 151,052,849 | $528,694,287 | +$149,920,554 | $3.50 | 124 |
| 2025 Q2 | 108,253,035 | $281,458,749 | +$738,261 | $2.60 | 103 |
| 2025 Q1 | 108,444,414 | $206,047,938 | +$13,824,994 | $1.90 | 107 |
| 2024 Q4 | 101,374,021 | $146,996,022 | +$1,180,763 | $1.45 | 92 |
| 2024 Q3 | 92,186,861 | $169,597,729 | +$881,089 | $1.84 | 79 |
| 2024 Q2 | 92,861,661 | $93,412,908 | -$5,271,746 | $1.00 | 81 |
| 2024 Q1 | 94,552,324 | $187,180,490 | +$18,089,983 | $1.98 | 77 |
| 2023 Q4 | 86,111,898 | $134,344,397 | -$2,317,455 | $1.56 | 76 |
| 2023 Q3 | 89,720,729 | $176,712,745 | -$1,697,948 | $1.97 | 76 |
| 2023 Q2 | 90,478,972 | $287,651,504 | +$28,216,829 | $3.18 | 72 |
| 2023 Q1 | 81,516,748 | $266,518,963 | +$1,871,389 | $3.27 | 72 |
| 2022 Q4 | 79,833,267 | $401,391,571 | +$78,919,542 | $5.03 | 54 |
| 2022 Q3 | 63,858,418 | $145,631,000 | +$3,917,942 | $2.28 | 36 |
| 2022 Q2 | 61,892,616 | $163,922,000 | +$665,806 | $2.65 | 31 |
| 2022 Q1 | 62,376,106 | $85,353,000 | -$4,074,753 | $1.37 | 33 |
| 2021 Q4 | 63,567,962 | $201,611,000 | +$198,091,000 | $3.17 | 37 |